Polyanionic polymer adjuvants for haemophilus influenzae B saccharide vaccines
AssigneeGlaxoSmithKline Biologicals, S.R.
InventorsNathalie Marie-Josephe Garcon, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide of H. influenzae B (PRP). Immunogenic compositions and methods of making such compositions are presented in which the PRP is surprisingly protected from immune interference by adding a polyanionic polymer (such as PLG-poly-L-glutamic acid) to the composition.
Claims1
An immunogenic composition comprising capsular polyribosylribitol phosphate (PRP) polysaccharide of Haemophilus influenzae B, poly-L-glutamic acid (PLG), diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin (FHA), pertactin, inactivated polio virus and Hepatitis B surface antigen.
Dependencies are inferred from the claim text.